Recent news on Natrecor

Cleveland Heart Doctor Is Drug Watchdog  -  May 22, 2007
WTOP,He was the only FDA adviser to vote against Natrecor, a heart failure drug that some research has tied to a risk of death.

The Drug Companies Get Tobacco Stained  -  May 22, 2007
24/7 Wall St.,He has been involved in studies that found health risks in Merck's (MRK) Vioxx, Johnson & Johnson’s (JNJ) Natrecor, a heart-failure treatment,

Open Source Drug Safety?  -  May 22, 2007
Forbes,J&J's (nyse: JNJ - news - people ) Natrecor, for heart failure, saw its sales plummet after to cardiologists called its safety into question.

Pushed Sales of Procrit  -  May 10, 2007
Wall Street Journal (subscription),...an anti-seizure medication sold by J&J's Ortho-McNeil Pharmaceutical unit; heart drug Natrecor sold by the Scios unit -- have drawn federal probes.

ACC: No Role for Outpatient Nisiritide (Natrecor) in Decompensated ...  -  Mar 27, 2007
MedPage Today,NEW ORLEANS, March 27 -- In the largest trial of stage D heart failure, nesiritide (Natrecor) showed no benefit as outpatient therapy, yet there was no

Scios Announces Results From Exploratory Nesiritide Study ...  -  Apr 5, 2007
Drug Newswire (press release),NATRECOR(R) is the only FDA-approved intravenous treatment for patients with acutely decompensated congestive heart failure (ADHF) who have dyspnea

Earnings Preview: Johnson & Johnson  -  Apr 16, 2007
BusinessWeek...federal subpoenas over how its antipsychotic medication Risperdal, migraine treatment Topamax and shortness of breath treatment Natrecor were marketed.

Study: Scios drug safe  -  Mar 28, 2007
Inside Bay Area,A new study bolsters the contention of executives at Mountain View-based Scios Inc. that their controversial heart drug, Natrecor, is safe — although the

Heart drug doesn’t help survival  -  Apr 10, 2007
Wilkes Barre Times-Leader,That drug — Natrecor — looked to be a blockbuster, but many doctors avoid it because of worries that it might raise the risk of death.

Anemia drug trial's tardiness at issue  -  Apr 20, 2007
Los Angeles Times,Some studies in 2005 suggested that the drug, sold under the brand name Natrecor, could cause kidney problems and death.

New perspectives on vasoactive therapy in heart failure management  -  Apr 2, 2007
TheHeart.Org,The role of nesiritide (Natrecor®, Scios/Johnson & Johnson) became controversial after a pooled analysis of three randomized controlled trials published in

Nesiritide Fails to Improve Outcomes for at-Home Heart Failure ...  -  Mar 29, 2007
DG NewsNEW ORLEANS, LA -- March 29, 2007 -- An attempt to expand use of the heart failure drug nesiritide (Natrecor) from in-hospital use to at-home use failed to

Johnson & Johnson's Natrecor Found to Be Safe - and Ineffective  -  27 Mar 2007
Seeking Alpha,Johnson & Johnson's heart drug Natrecor has been proven safe - so safe, in fact, that a study has concluded it is ineffective in treating acute and chronic

Study Supports Safety of Heart Drug, but Not Its Effectiveness  -  27 Mar 2007
Tuscaloosa News (subscription),A new study presented at a cardiology conference yesterday might allay some fears about the safety of Johnson & Johnson’s controversial heart drug, Natrecor

Study: New heart failure drug helps symptoms but not survival  -  27 Mar 2007
Coos Bay World,That drug - Natrecor - looked to be a blockbuster, but many doctors avoid it because of worries that it might raise the risk of death.

FUSION 2: No advantage to outpatient nesiritide infusions in ...  -  27 Mar 2007
TheHeart.Org,New Orleans, LA - Weekly or twice-weekly outpatient infusions of nesiritide (Natrecor, Scios/Johnson & Johnson) do not prolong survival or prevent future

Around the Web in 80 Seconds with Citigroup, Johnson & Johnson ...  -  27 Mar 2007
Schaeffers Research,...study involving 920 patients showed that Johnson & Johnson's (JNJ) new heart drug, Natrecor, is safe, allaying earlier concerns about kidney problems.

Wall Street Breakfast  -  27 Mar 2007
Seeking Alpha,Johnson & Johnson's heart drug Natrecor has been proven safe - so safe, in fact, that a study has concluded it is ineffective in treating acute and chronic

Media Digest 3/26/2007 Reuters, WSJ, NYTime, FT, Barron's  -  27 Mar 2007
24/7 Wall St.,The New York Times reports that heart drug Natrecor from Johnson & Johnson did not work in the population used for a study of the medication.

Johnson & Johnson gets subpoenas related to Risperdal, Topamax and ...  -  Mar 12, 2007
Brandon Sun,The drugs at issue are Risperdal, a treatment for schizophrenia and bipolar mania, the epilepsy treatment Topamax, and Natrecor, which is used to treat

New heart failure drug helps symptoms but not survival, study finds  -  Mar 25, 2007
The State,That drug — Natrecor — looked to be a blockbuster, but many doctors avoid it because of worries that it might raise the risk of death.

J&J hit with new batch of subpoenas  -  Mar 13, 2007
San Francisco Chronicle,..."The US attorney's office for the Northern District of California is investigating Scios' marketing and promotion of Natrecor,'' Macaulay said in an e-mail.

J&J Gets US Subpoenas on Marketing of Three Drugs  -  Mar 12, 2007
Reuters.uk,The drugs being investigated are Risperdal, sold by J&J unit Janssen; Topamax, sold by unit Ortho-McNeil; and Natrecor, sold by its Scios subsidiary.

3 drugs at issue in subpoenas  -  Mar 12, 2007
Boston Globe,The drugs at issue are Risperdal, a treatment for schizophrenia and bipolar mania, the epilepsy treatment Topamax, and Natrecor, for heart-failure patients,

Johnson & Johnson gets subpoenas on three drugs  -  Mar 13, 2007
Philadelphia Inquirer,Scios, a third J&J subsidiary, in July 2005 received a subpoena from the US attorney in Boston related to marketing of its heart-failure drug Natrecor,

AFX TOP STORIES Global 1605 GMT  -  Mar 12, 2007
Forbes,Risperdal is sold by Janssen LP, Topamax by Ortho-McNeil, and Natrecor by Scios Inc. DETROIT (AP) - Cash-strapped Ford Motor Co. has sold a controlling

J&J gets federal subpoenas on drug sales  -  Mar 12, 2007
Boston Globe,Risperdal is sold by Janssen LP, Topamax by Ortho-McNeil, and Natrecor by Scios Inc. J&J said the subpoenas related to previously announced probes by the

AFX TOP STORIES Global 1605 GMT  -  Mar 12, 2007
FXstreet.com The Futures Market,Risperdal is sold by Janssen LP, Topamax by Ortho-McNeil, and Natrecor by Scios Inc. Ford sells major stake in Aston Martin DETROIT (AP) - Cash-strapped

Johnson & Johnson subpoenaed over marketing practices  -  Mar 12, 2007
Asbury Park Press,...schizophrenia drug Risperdal, the seizure medication Topamax and the congestive heart failure treatment Natrecor, the company said today in a statement.

J&J receives subpoenas over three drugs  -  Mar 12, 2007
United Press International12 (UPI) -- Johnson & Johnson said Monday it got subpoenas from three US attorneys' offices related to probes into Risperdal, Topamax and Natrecor.

A Heart-Pumping Meeting  -  Mar 23, 2007
Forbes,A trial of Natrecor, a controversial Johnson & Johnson heart failure drug, will test whether regular, outpatient infusions of the drug help patients.

The ticker  -  Mar 12, 2007
Boston Herald,Risperdal, a treatment for schizophrenia and bipolar mania, the epilepsy treatment Topamax, and Natrecor, which is used to treat heart-failure patients.

Johnson & Johnson receives subpoenas BRIEFING: NEW YORK:  -  Mar 13, 2007
Therapeutics Daily (subscription) (press release),...promotion of the schizophrenia drug Risperdal, the seizure medication Topamax and the congestive heart failure treatment Natrecor, the company said.

Drug Maker Subpoenaed About Marketing  -  Mar 12, 2007
New York Times,The drugs at issue are Risperdal, a treatment for schizophrenia and bipolar mania; Topamax, an epilepsy treatment; and Natrecor, which is used to treat

IN BRIEF | PHARMACEUTICALS  -  Mar 13, 2007
Therapeutics Daily (subscription) (press release),The drugs at issue are Risperdal, a treatment for schizophrenia and bipolar mania; the epilepsy treatment Topamax; and Natrecor, which is used to treat

Johnson & Johnson gets subpoenas on three drugs  -  Mar 13, 2007
Therapeutics Daily (subscription) (press release),...concern promotion of the schizophrenia drug Risperdal, the seizure medication Topamax and the heart-failure treatment Natrecor, the company said.

J&J hit with new batch of subpoenas  -  Mar 13, 2007
Therapeutics Daily (subscription) (press release),...part of an investigation into marketing practices for three drugs, including the heart failure remedy Natrecor developed by the company's Scios unit in

Johnson & Johnson Subpoenaed on Marketing of Three Drugs  -  Mar 13, 2007
Seeking Alpha,...marketing of three prescription drugs: bestselling antipsychotic Risperdal, epilepsy and migraine drug Topamax, and heart failure medication Natrecor.

J&J Gets Subpoenas  -  Mar 12, 2007
TheStreet.comSpecifically, they cover three products made by J&J units -- Risperdal by Janssen, Topamax by Ortho-McNeil and Natrecor by Scios.

Johnson & Johnson subpoenaed on drugs -  -  Mar 12, 2007
Carib Journal...a treatment for schizophrenia and bipolar disorder; Topamax, an epileptic seizures treatment; and Natrecor, used to treat heart-failure patients,

Johnson & Johnson receives subpoenas  -  Mar 12, 2007
Prdomain Business Register (press release),...to sales and marketing of RISPERDAL® by Janssen, LP, TOPAMAX® by Ortho-McNeil and NATRECOR® by Scios Inc. – each subsidiaries of Johnson & Johnson.

Johnson & Johnson Receives Subpoenas  -  Mar 12, 2007
PR Newswire (press release),...respectively, to sales and marketing of RISPERDAL by Janssen, TOPAMAX by Ortho-McNeil and NATRECOR by Scios -- each subsidiaries of Johnson & Johnson.

J&J hit by subpoenas over sales practices  -  Mar 12, 2007
CNNMoney.com...a schizophrenia drug from its Janssen unit, Topamax, a migraine drug from its Ortho-McNeil unit, and Natrecor, a heart failure treatment from its Scios

J&J gets US subpoenas on marketing of three drugs  -  Mar 12, 2007
ReutersThe drugs being investigated are Risperdal, Topamax, and Natrecor. ((Reporting by Kim Dixon, editing by Gerald E. McCormick; Reuters Messaging;

Johnson & Johnson receives subpoenas over supervision of some ...  -  Mar 12, 2007
Forbes,...of the sales and marketing of the drugs Risperdal by Janssen, Topamax by Ortho-McNeil and Natrecor by Scios -- each subsidiaries of Johnson & Johnson.

J&J gets US subpoenas on marketing of three drugs  -  Mar 12, 2007
Reuters...to previously disclosed probes over the company's oversight of three of its subsidiaries. The drugs being investigated are Risperdal, Topamax, and Natrecor.

Johnson & Johnson receives subpoenas for three drugs  -  Mar 12, 2007
newratings.com...in the investigation that involves schizophrenia drug, Risperdal, the seizure medication, Topamax, and the congestive heart failure treatment Natrecor.

Johnson & Johnson Subpoenaed  -  Mar 12, 2007
NJBIZ,...promotion of its schizophrenia drug Risperdal, the seizure medication Topamax, and the congestive heart failure treatment Natrecor, the company said.

J&J gets subpoenas related to 3 drugs  -  Mar 12, 2007
Eyewitness News,The drugs in question are Risperdal, a treatment for schizophrenia and bipolar mania; Topamax, a treatment for epilepsy; and Natrecor, which is used to

Market Report -- In Play (JNJ)  -  Mar 12, 2007
MSN Money...respectively, to sales and marketing of RISPERDAL by Janssen, TOPAMAX by Ortho-McNeil and NATRECOR by Scios -- each subsidiaries of JNJ.

Sector Snap: Heart Therapy Makers  -  Mar 23, 2007
Forbes,...the Cypher, and data on the safety and effectiveness of its approved heart drug Natrecor, which some critics claim raises the risk of patient death.

Research Suggests Natrecor(R) (Nesiritide) Improves Postoperative ...  -  Feb 7, 2007
Drug Newswire (press release),Those taking Natrecor(R) had improved outcomes, including shorter hospital stays and a statistically significant decrease in mortality rate after 180 days

Research Suggests Natrecor(R) (Nesiritide) Improves Postoperative ...  -  Feb 5, 2007
Earthtimes.org5 -- Natrecor(R) (nesiritide) may be beneficial in the prevention of renal dysfunction after coronary artery bypass grafting requiring cardiopulmonary

Heart medication protects kidneys, study reveals  -  Feb 17, 2007
Bradenton Herald,Natrecor, given intravenously before and after bypass surgery, helped prevent the problem, reduced costly hospital stays and improved the survival of

Drug may improve post-op outcomes for bypass patients  -  Feb 13, 2007
Asbury Park Press,The drug nesiritide (trade name Natrecor) may help prevent kidney dysfunction and improve survival in patients who've had coronary artery bypass grafting

Drug May Improve Post-Op Outcomes for Bypass Patients  -  Feb 13, 2007
HealthCentral.com,12 (HealthDay News) -- The drug nesiritide (trade name Natrecor) may help prevent kidney dysfunction and improve survival in patients who've had coronary

Maxygen Appoints Santosh Vetticaden, MD, Ph.D., as Chief Medical ...  -  Feb 21, 2007
PharmaLive.com (press release),In this position, Dr. Vetticaden led all of the company's clinical programs from Phase I through Phase IV, including Scios' marketed drug, Natrecor(R).

Maxygen Appoints Santosh Vetticaden, MD, Ph.D., as Chief Medical ...  -  Feb 21, 2007
Yahoo! News (press release)In this position, Dr. Vetticaden led all of the company's clinical programs from Phase I through Phase IV, including Scios' marketed drug, Natrecor®.

"Exploratory" study suggests nesiritide protects kidneys during ...  -  Feb 5, 2007
TheHeart.Org,Washington, DC - Perioperative infusion of nesiritide (Natrecor, Scios/Johnson & Johnson) apparently blunted the adverse renal effects of pump-supported

(PRN) - Black Hills Corporation Announces 37th Consecutive Annual ...  -  Feb 5, 2007
Bolsamania.com,...(PRN) - Research Suggests Natrecor(R) (Nesiritide) Improves Postoperative Renal Function and Potentially Enhances Survival After Coronary Artery Bypass

SUNSET, SUNRISE  -  Dec 31, 2006
San Francisco Chronicle,During his 25-year career, he developed two drugs, Natrecor and Integrilin, used to prevent heart attacks and improve the lives of those facing heart

ZymoGenetics Hires New VP Commercial Manufacturing  -  Dec 19, 2006
PharmaLive.com (press release),He joins ZymoGenetics from Scios Inc., a JNJ company, where he was responsible for building and managing all manufacturing operations for Natrecor,

HIV drug maker receives subpoena  -  Dec 9, 2006
Contra Costa Times,Although the FDA has approved Natrecor's sale to people with congestive heart failure who have trouble breathing while doing minimal activity,

PHARMACEUTICAL COMPANIES ARE UNDER FEDERAL SCRUTINY FOR PROMOTING ...  Oct 22, 2006
By Steve Johnson. The heart-failure drug Natrecor seemed sure to become a blockbuster after Scios of Fremont put it on the market in 2001. ... -San Jose Mercury News, San Mateo County Times - Oct. 29, 2006  Oct 29, 2006
The heart-failure drug Natrecor seemed sure to become a blockbuster after Scios of Fremont put it on the market in 2001. Besides ... -Therapeutics Daily (subscription) (press release), Arca Discovery welcomes biotech veteran  Nov 6, 2006
...of Sunnyvale, Calif., to Johnson & Johnson for $2.4 billion in 2003. Scios brought to market the cardiovascular drug Natrecor. Brewer ... -Denver Business Journal, ARCA Discovery Names Richard B. Brewer President and Chief ...  Nov 6, 2006
Mr. Brewer was president and CEO of Scios, Inc., where he led the company through the successful approval and launch of Natrecor® (nesiritide), the first new ... -Yahoo! News (press release) J&J reaps benefits from diversity  Oct 17, 2006
...business was forced to try to offset some generic competition and some product disappointments, including concerns over and less use of Natrecor, a heart ... -MSN Money Nesiritide use by clinicians fell fast after negative reports ...  Oct 20, 2006
St Louis, MO - When reports in two prominent journals raised red flags on giving nesiritide (Natrecor, Scios/Johnson & Johnson) to patients with acute ... -TheHeart.Org, New Jersey business briefs  Oct 18, 2006
NEW BRUNSWICK -- Use of Johnson & Johnson's Natrecor plunged two-thirds last year after two studies linked the heart-failure drug to kidney damage and death. ... -NorthJersey.com, Bayer To Investigate Drug Safety Mistake  Oct 13, 2006
Even barely known drugs given mostly in hospitals, such as Trasylol or the heart failure medicine Natrecor made by Johnson and Johnson (nyse: JNJ - news ... -Forbes, UPDATE 1-J&J's says Natrecor meets goals in midstage trial  Sep 11, 2006
...unit on Monday said its heart failure drug Natrecor helped to maintain kidney function and to reduce death in a mid-stage study of heart failure patients who ... -Reuters

UPDATE 2-J&J says Natrecor meets goals in midstage trial  Sep 11, 2006
...unit said on Monday its heart failure drug, Natrecor, is as safe overall as a placebo in a mid-stage study of heart failure patients who underwent heart bypass ... -Reuters

J&J's says Natrecor meets goals in midstage trial  Sep 11, 2006
CHICAGO, Sept 11 (Reuters) - Johnson & Johnson's(JNJ.N: Quote, Profile, Research) Scios unit on Monday said its heart failure drug Natrecor helped maintain ... -Reuters

J&J Names Institute to Lead Trial of Its Natrecor Heart Drug  Sep 7, 2006
...& Johnson's Scios unit named Duke Clinical Research Institute to lead a 7,000-patient trial to test the safety and efficacy of its heart-failure drug Natrecor. ... -Wall Street Journal (subscription)

Investigators Report New Renal, Mortality And Safety Data From ...  Sep 12, 2006
NAPA (Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery) trial, a Scios Inc.-sponsored study that evaluated NATRECOR(R) (nesiritide ... -Medical News Today

Scios Selects Duke Clinical Research Institute (DCRI) to Lead ...  Sep 7, 2006
This independent, global, multi-center outcomes study of approximately 7,000 patients will further assess the benefit and safety profile of NATRECOR(R) in ... -PR Newswire

J&J unit commissions safety test of heart failure drug  Sep 8, 2006
...unit has commissioned the Duke Clinical Research Institute to perform a study of the safety and effectiveness of its heart failure drug Natrecor. ... -Kansas.com

Scios Selects Duke Clinical Research Institute (DCRI) to Lead ...  Sep 7, 2006
...independent, global, multi-center outcomes study of approximately 7,000 patients will further assess the benefit and safety profile of NATRECOR® in patients ... -Yahoo! News

Medivation Appoints Dr. Andrew A. Protter Vice President of ...  Sep 14, 2006
At Scios, which was acquired in 2003 by Johnson & Johnson, Dr. Protter had responsibility for all preclinical development activities on Natrecor(R) - a ... -Business Wire

Clinic doctors to study drug they questioned  Sep 8, 2006
The trial, which will include 7,000 patients worldwide, will assess whether the benefits of Natrecor exceed the risks, said Dr. Steven Nissen, the Clinic's ... -Cleveland Plain Dealer

Nesiritide shows hint of survival benefit in chronic-HF patients ...  Sep 12, 2006
Seattle, WA - Perioperative infusion of nesiritide (Natrecor, Scios/Johnson & Johnson) was associated with reductions in mortality over six months among ... -TheHeart.Org

NICE Welcomes Referral Of New Work Programme Topics, UK  Aug 31, 2006
...for atrial fibrillation; lerdelimumab (CAT-152) for glaucoma; carmustine implants (Gliadel Wafers) for glioma (recurrent); nesiritide (Natrecor) for acute ... -Medical News Today

HIV drug maker receives subpoena  -  Dec 9, 2006
Contra Costa Times,Johnson & Johnson, has acknowledged that the US attorney in San Francisco is investigating it for allegedly engaging in off-label marketing of its drug Natrecor ...

Scios Announces Selection of Independent Executive Committee and ...  -  Nov 13, 2006
PR Newswire (press release),...in the acute heart failure field, is being conducted to further assess important clinical outcomes as well as the benefit and safety profile of NATRECOR(R) in ...

Scios Announces Selection of Independent Executive Committee and ...  -  Nov 13, 2006
Yahoo! News (press release)...acute heart failure field, is being conducted to further assess important clinical outcomes as well as the benefit and safety profile of NATRECOR® in patients ...

US Stock-Index Futures Are Little Changed; Tyco Declines  -  Nov 15, 2006
BloombergPatients using Natrecor, a heart-failure drug sold by J&J's Scios Inc. unit, may switch to a new treatment developed by Astellas Pharma Inc. ...

(PRN) - Aeronautics Funding, Export-Import Bank Extension ...  -  Nov 13, 2006
Bolsamania.com,Selection of Independent Executive Committee and Planned Protocol Design for the ASCEND-HF Landmark International Outcomes Trial of NATRECOR(R) (nesiritide ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional